China CRO Company,Preclinical research services

encnjpkr

News

Our Events

Location:Home > News Center > Our Events > Shanghai - Boston Dr...

Shanghai - Boston Drug Development International Collaboration Seminar Ended Successfully

Author:   Datetime:2016-08-25  Hits:

    On Aug 24th, Medicilon co-hosted the “Shanghai – Boston Drug Development International Collaboration Seminar” with Shanghai Center of Biomedicine Development and Shanghai Zhangjiang Biotech&Pharmaceutical Base Development Co., Ltd. at Hyatt Regency Hotel, Cambridge, MA.  At the same time, Medicilon hosted the “Client Appreciation Dinner”.  Over 60 guests from pharmaceutical industry and academic institutions in Boston attended the event.


    During the seminar, both Dr. Junying Yuan, Fellow of American Academy of Art and Sciences and Tenured Professor at Harvard University, and Dr. Liming Shao, Distinguished Professor at Fudan University, delivered a concise speech, respectively.



          Dr. Chunlin Chen, Dr. Junying Yuan, Professor Liming Shao          (From left to right)


    Dr. Yuan introduced the Chinese Institute, which bridged the collaboration of pharmaceutical industry between Boston and Shanghai.  Dr. Yuan also reiterated the successfully collaboration between US and China led by Medicilon.  Professor Shao compared the development of pharmaceutical industry between Boston and Shanghai.  Professor Shao also introduced the pharmaceutical industry in Shanghai from a prospective in development and used Medicilon as an example to illustrate the collaboration experience between the businesses in Shanghai Zhangjiang.



Dr. Junying Yuan shared the experience with the guest.



Professor Liming Shao listened to the sharing by other speaker.


    As a pharmaceutical representative of Zhangjiang Hi-tech Zone, Medicilon has the full support from the Shanghai government.  Medicilon hosted the “Client Appreciate Dinner” during the seminar at Hyatt Regency Hotel.  Medicilon CEO, Dr. Chunlin Chen, delivered an opening statement and introduced the development strategy of Medicilon for next few years, during which he shared with the audience several case studies in international collaboration as well as the government policies in China.  Dr. Chen said, “Base on the approved and completed set of new drug approvals, Medicilon will take efforts to strengthen the chemical formulations CGMP, expand the laboratory and tumor animal models, develop the platform and provide faster and better service for clients.”



Dr. Chunlin Chen delivered an opening statement.


    During the dinner banquet, Medicilon invited a well-known local band, “Jazz-in-the-air”, to perform and had a raffle drawing for the guests.  Clients were happy to share the collaboration experience between Medicilon and to give their suggestions during the dinner.  Medicilon would like to thank for the colleagues from Boston, especially the SAPA and CABA organizations, which strongly support Medicilon on the collaboration between US and China.



Dr. Chunlin Chen and the guest.



Guests were exchanging experiences during the event.



Guests were exchanging experiences during the event.



Guests were exchanging experiences during the event.


    The seminar and dinner was organized by Dr. Zhaohua Lu and Dr. Wenying Liu, who are the representatives of Medicilon’s Boston office.  Medicilon was established in 2004 as a joint venture company with a US pharmaceutical company.  In order to coordinate with the Shanghai office on the global strategy, Medicilon officially established its office at Boston in March 2016.  Shanghai and Boston were chosen as a starting point for Medicilon in China and US, respectively.  During the 12 years of endeavor, Medicilon has facilitated hundreds of collaborations between the local companies in Shanghai and Boston.

Prev:Medicilon October Prospecting Trip in New Jersey

Next:Medicilon Boston Office Officially Opened